Pluristem Therapeutics Inc. (NASDAQ:PSTI) Major Shareholder Acquires $434,240.00 in Stock

Pluristem Therapeutics Inc. (NASDAQ:PSTI) major shareholder Clover Wolf Capital – Limited purchased 59,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $7.36 per share, for a total transaction of $434,240.00. Following the completion of the transaction, the insider now directly owns 3,270,760 shares in the company, valued at $24,072,793.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Clover Wolf Capital – Limited also recently made the following trade(s):

  • On Monday, June 29th, Clover Wolf Capital – Limited bought 110,897 shares of Pluristem Therapeutics stock. The stock was purchased at an average cost of $8.41 per share, with a total value of $932,643.77.
  • On Wednesday, June 24th, Clover Wolf Capital – Limited purchased 25,000 shares of Pluristem Therapeutics stock. The shares were purchased at an average cost of $8.05 per share, for a total transaction of $201,250.00.
  • On Thursday, June 18th, Clover Wolf Capital – Limited purchased 49,000 shares of Pluristem Therapeutics stock. The stock was purchased at an average cost of $7.36 per share, with a total value of $360,640.00.
  • On Wednesday, June 10th, Clover Wolf Capital – Limited acquired 25,000 shares of Pluristem Therapeutics stock. The stock was purchased at an average price of $6.91 per share, with a total value of $172,750.00.
  • On Monday, June 8th, Clover Wolf Capital – Limited bought 178,717 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.36 per share, for a total transaction of $1,315,357.12.
  • On Thursday, June 4th, Clover Wolf Capital – Limited bought 7,610 shares of Pluristem Therapeutics stock. The stock was acquired at an average cost of $7.86 per share, with a total value of $59,814.60.
  • On Tuesday, June 2nd, Clover Wolf Capital – Limited purchased 117,489 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $7.57 per share, for a total transaction of $889,391.73.
  • On Sunday, May 31st, Clover Wolf Capital – Limited acquired 1,797 shares of Pluristem Therapeutics stock. The shares were acquired at an average price of $7.95 per share, for a total transaction of $14,286.15.
  • On Wednesday, May 27th, Clover Wolf Capital – Limited acquired 90,000 shares of Pluristem Therapeutics stock. The stock was acquired at an average price of $8.14 per share, with a total value of $732,600.00.

Shares of NASDAQ PSTI opened at $8.67 on Friday. Pluristem Therapeutics Inc. has a fifty-two week low of $2.82 and a fifty-two week high of $13.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.47 and a current ratio of 2.47. The business has a 50-day moving average of $8.14 and a 200-day moving average of $6.01.

PSTI has been the topic of a number of research reports. Jefferies Financial Group assumed coverage on shares of Pluristem Therapeutics in a research note on Friday, June 19th. They issued a “buy” rating and a $12.00 price target on the stock. ValuEngine cut shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Zacks Investment Research cut Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 30th. Dawson James restated a “buy” rating on shares of Pluristem Therapeutics in a report on Wednesday, April 15th. Finally, Maxim Group reiterated a “buy” rating and set a $12.00 price objective on shares of Pluristem Therapeutics in a report on Friday, May 15th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $12.20.

A number of hedge funds have recently bought and sold shares of PSTI. Renaissance Technologies LLC raised its position in Pluristem Therapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 273,419 shares of the biotechnology company’s stock worth $1,077,000 after acquiring an additional 87,188 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Pluristem Therapeutics by 303.9% during the 4th quarter. Jane Street Group LLC now owns 67,349 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 50,674 shares during the last quarter. Levin Capital Strategies L.P. bought a new stake in shares of Pluristem Therapeutics in the 1st quarter valued at about $37,000. Finally, ETF Managers Group LLC lifted its stake in Pluristem Therapeutics by 9.8% in the 1st quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 5,764 shares during the last quarter. Hedge funds and other institutional investors own 7.82% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Recommended Story: How a Back-End Load Mutual Fund Works

Insider Buying and Selling by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.